Skip to content

Supporting Development of Diagnostic Tests for Unmet Needs

Supporting Development of Diagnostic Tests for Unmet Needs

Friends of Cancer Research Virtual Meeting

Supporting Development of Diagnostic Tests for Unmet Needs

Thank you to all that attended! To view the meeting again in full, click HERE.

To access the meeting white paper, click HERE.

Tuesday, February 22, 2022
12:00PM EST – 1:00PM EST

Friends of Cancer Research (Friends) is proud to announce a new virtual meeting, Supporting Development of Diagnostic Tests for Unmet Needs.

During the past several months, experts from across health sectors have convened to design new approaches for drug/diagnostic co-development in the field of oncology and rare diseases. This forum will feature a new report describing recommended strategies and policy considerations to optimize diagnostic test development for rare populations into the future.

Drug and diagnostic co-development has traditionally occurred in a manner by which one drug is accompanied by one diagnostic test. However, this paradigm may present challenges for patient access and trial accrual. Through this project we explore flexibilities to expedite development and review of targeted therapies and companion diagnostics (CDx) for rare biomarkers or indications.

Register for the meeting above and stay tuned for additional agenda updates. The current draft agenda is below.


12:00PM – Welcome & Opening Remarks

12:05PM – Keynote Presentation

  • Rep. Diana DeGette (D-CO)
  • Rep. Larry Bucshon (R-IN)

12:10pm – Panel Discussion: Developing Diagnostic Tests for Rare Biomarkers and Indications

  • Moderator: Megan Doyle, Amgen
  • Soma Ghosh, CDRH, U.S. FDA
  • Rasika Kalamegham, Genentech, A Member of the Roche Group
  • Jochen Lennerz, Massachusetts General Hospital
  • Elizabeth Mansfield, Foundation Medicine

12:40pm – Stakeholder Q&A and Next Steps

12:58PM – Closing Remarks